DUBLIN--(BUSINESS WIRE)--
ICON
plc, (NASDAQ:ICLR) global provider of drug development
solutions and services to the pharmaceutical, biotechnology and medical
device industries, today announced the appointment of Mr. Ronan Murphy
as a non-executive director.
Mr. Murphy is the former Senior Partner of PwC, Ireland's largest
professional services firm with almost 100 partners and employing over
2,000 people. Mr. Murphy was elected Senior Partner in 2007 and was
re-elected for a further four year term in 2011. Following completion of
the maximum two terms, Mr. Murphy retired from the firm in June 2015.
Mr. Murphy was also a member of the PwC EMEA Leadership Board for a five
year period from 2010 to 2015.
Mr. Murphy joined PwC in 1980 and was admitted to the Partnership in
1992. As an Assurance Partner, he served clients across many sectors. In
1995, Mr. Murphy joined the firm's leadership team and held a number of
operational leadership roles, prior to being appointed as Partner in
Charge of the firm's Assurance Practice in 2003, a position he held for
four years prior to his appointment as Senior Partner.
In early 2016, Mr. Murphy was appointed as a non-executive director of
Davy Stockbrokers, and he chairs their Audit Committee. He is also a
Director of Liberty Insurance's operations in Ireland and also chairs
the Audit Committee.
Mr. Murphy currently serves as a Board Member of the UCD Michael Smurfit
Business School and is a founding Board Member of the British Irish
Chamber of Commerce.
Mr. Murphy completed a Bachelor of Commerce and Masters in Business
Studies at University College Dublin before qualifying as a chartered
accountant in 1982.
"I am very pleased that Mr. Murphy has joined the board"
commented Mr. Declan McKeon, acting Chairman of the Board. "His
leadership of PwC, Ireland's largest professional services firm, and his
extensive business experience and expertise across many industry sectors
will bring invaluable expertise to the ICON board".
About ICON plc
ICON plc is a global provider of drug development solutions and services
to the pharmaceutical, biotechnology and medical device industries. The
company specialises in the strategic development, management and
analysis of programs that support clinical development - from compound
selection to Phase I-IV clinical studies. With headquarters in Dublin,
Ireland, ICON currently, operates from 88 locations in 37 countries and
has approximately 12,600 employees.
Further information is available at www.iconplc.com.
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and industry
conditions. These statements are not guarantees of future performance or
actual results, and actual results, developments and business decisions
may differ from those stated in this press release. The forward-looking
statements are subject to future events, risks, uncertainties and other
factors that could cause actual results to differ materially from those
projected in the statements, including, but not limited to, the ability
to enter into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the integration of
new business mergers and acquisitions, as well as economic and global
market conditions and other risks and uncertainties detailed from time
to time in SEC reports filed by ICON, all of which are difficult to
predict and some of which are beyond our control. For these reasons, you
should not place undue reliance on these forward-looking statements when
making investment decisions. The word "expected" and variations of such
words and similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they are
made and we do not undertake any obligation to update publicly any
forward-looking statement, either as a result of new information, future
events or otherwise. More information about the risks and uncertainties
relating to these forward-looking statements may be found in SEC reports
filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are
available on the SEC's website at http://www.sec.gov.
ICON/ICLR-F
View source version on businesswire.com: http://www.businesswire.com/news/home/20161024005521/en/
ICON plc
Contact:
Investor Relations
1-888-381-7923
or
Brendan
Brennan
Chief Financial Officer
+ 353 -1-291-2000
or
Simon
Holmes
EVP Investor Relations and Corporate Development
+ 353
-1-291-2000
Source: ICON plc
News Provided by Acquire Media
